A retatrutide certificate of analysis (CoA) is a laboratory document describing what one identified batch of synthetic peptide was found to contain: its identity, its chromatographic purity, and in better cases its net peptide content. It records composition at a single point in time, for material sold for research use only. It is not a safety clearance and it says nothing about use. The useful question is narrower: does this document contain enough verifiable detail to show that the vial in front of you holds the molecule printed on the label?
What should a retatrutide CoA actually contain?
Five entries do most of the evidential work on any peptide certificate, and a document missing one of them is weaker than it appears:
- Identity by mass spectrometry, with the observed molecular mass shown next to the expected mass for the sequence.
- Purity by HPLC (high-performance liquid chromatography), reported as a percentage of total peak area, with the chromatogram attached.
- Net peptide content, a separate figure from both purity and the fill amount stated on the vial.
- A batch or lot number matching the number printed on the vial you received.
- A date of analysis plus the name of the laboratory that performed it.
Everything else (appearance, water content, residual solvents) is useful but secondary. The general anatomy of these fields, and the ways they get padded, is covered in more depth in our guide on how to read a peptide CoA. Here the focus is on what changes when the compound is retatrutide.
Why does identity matter more for a newer, larger peptide?
Retatrutide is a comparatively recent arrival in the research-peptide market and a longer, more structurally complex molecule than the short peptides that have circulated for decades. Two consequences follow for its documentation. First, long-chain synthesis generates a wider family of closely related by-products: chains missing a single amino acid residue, incompletely deprotected intermediates, oxidised or otherwise modified variants. Several of these differ from the target by only a small shift in retention time and can sit beside or underneath the main peak. Second, far fewer buyers have any reference point for what the material should be, so a mislabelled or substituted compound is less likely to be noticed by anyone downstream.
That combination is where the principle identity and purity answer different questions stops being academic. A sample can be 99% pure and still be the wrong molecule, or the right molecule shortened by one residue. Only a mass measurement rules that out, which is why the MS section is the first thing to read on this particular certificate.
How does mass spectrometry confirm retatrutide identity?
Mass spectrometry (MS), usually coupled to liquid chromatography as LC-MS, measures the mass-to-charge ratio of ionised molecules, producing a mass that can be compared against the mass calculated from the published amino acid sequence. A credible identity section therefore states three things: the method used, the expected molecular mass, and the observed molecular mass, so a reader can see for themselves that the two agree within the stated tolerance of the instrument. Electrospray ionisation of a larger peptide commonly produces multiply charged ions, so you may see several charge states rather than one value; a spectrum or peak list is stronger evidence than a single printed figure.
What does not qualify is an identity line reading conforms or passes with no masses shown. That is an assertion, not a measurement, and it cannot be checked by anyone. The division of labour between the two core methods is unpacked in our comparison of HPLC and mass spectrometry in peptide testing.
What does HPLC purity tell you, and why do you need the chromatogram?
HPLC separates a sample into peaks and reports the target peak as a percentage of total peak area, for example 99.0%. That number is a ratio of areas under one specific set of conditions, nothing more. The chromatogram is the actual evidence, and looking at it answers what the percentage hides: is the baseline flat or noisy, is the main peak symmetrical or shouldered, are there small satellite peaks eluting close to it, was the run long enough for late-eluting impurities to appear, and is the detection wavelength stated? On a long peptide, a shoulder on the main peak is the visual signature of a closely related impurity that integration may have folded into the target area.
A purity percentage published with no chromatogram behind it is a weak signal, however high the figure. Treat the trace, not the number, as the claim being made.
Three tests, three different claims
| Test | Question it answers | Evidence to look for |
|---|---|---|
| HPLC | How much of the material is the target peak? | Percentage by area plus the chromatogram, wavelength and run time |
| MS or LC-MS | Is this the molecule claimed? | Expected mass next to observed mass, with spectrum or peak list |
| Amino acid analysis or nitrogen determination | How much actual peptide is in the powder? | Net peptide content stated as its own figure |
What is net peptide content, and how does it differ from the fill amount?
Purity is reported as a percentage by area. Net peptide content is a different measurement, determined by amino acid analysis (AAA) or nitrogen determination, and it accounts for everything in the powder that is not peptide: residual water, salts and counter-ions such as trifluoroacetate (TFA) or acetate. A lyophilised powder can be highly pure by HPLC and still be a modest proportion of peptide by weight, because purity describes the composition of the peptide fraction, not of the vial.
The fill amount is a third and separate thing: the nominal mass the vendor states it placed in the vial. A standard CoA does not usually verify fill weight at all, though many buyers assume it does. If the label gives a fill amount, the certificate gives purity, and neither document gives net peptide content, then the quantity of peptide actually present is undocumented. Transparent sellers publish all three figures and leave the arithmetic to the reader.
Does the batch number on the CoA match the vial?
This is the check most often skipped, and the one that invalidates every other field when it fails. A CoA describes one batch. If the lot number printed on your vial, box or label does not appear on the certificate, then the document is evidence about some other material. Generic certificates carrying no batch number at all, reused across an entire catalogue, are common in this market and are better read as marketing collateral than as analytical data.
Three practical questions settle it: does the certificate carry a batch or lot identifier, does that identifier match your physical vial character for character, and is the document specific to retatrutide rather than a template with a product name typed into it? A mismatch is not automatically deception, since relabelling and repackaging happen, but an unexplained mismatch stays unresolved until the vendor produces the certificate for your actual lot.
Why does the test date on a retatrutide CoA matter?
Results describe a batch at a point in time. The date of analysis lets you place that measurement relative to when the batch was produced and when you received it; without a date, the certificate is undatable and therefore unauditable. An undated document cannot be distinguished from one issued years earlier for entirely different material.
Peptides are also not inert over time. Lyophilised material held or shipped under poorly controlled conditions can degrade, so a purity figure from a test performed long before your vial left the warehouse is a historical statement rather than a current one. An older date is not disqualifying by itself; the point is that you should be able to see it. Look for the analysis date, the manufacture date of the lot where it is given, and whether the seller retests long-held stock or simply republishes the original certificate indefinitely.
Who issued the CoA, and can you verify it at the source?
A certificate is only as strong as the party that signed it. Look for a named laboratory, independent of the seller, with contact details and a traceable existence. Phrasing such as tested by a US lab, with no name attached, is unverifiable by design. Independent third-party testing houses operating in this market include Janoshik and MZ Biolabs among others, and ISO/IEC 17025, the international accreditation standard for the competence of testing laboratories, is a stronger signal than no accreditation at all.
The decisive feature is a verification mechanism: a code or QR that resolves on the laboratory's own domain and returns the same report, with the same batch number and the same figures. A PDF hosted only by the vendor can be edited in minutes and leaves no trail. Transparency is a documentary property, not a marketing claim, and source verification is what separates the two.
What are the red flags on a retatrutide CoA?
- No laboratory name, or a laboratory that cannot be shown to exist.
- A purity percentage with no chromatogram attached.
- An identity result stated only as a pass, with no expected and observed masses.
- One generic certificate reused across every product, with no batch number.
- CoAs available only by email on request, after purchase.
- A verification code, QR or portal that leads nowhere.
One non-flag deserves mention: a standard purity and identity CoA usually contains no sterility or endotoxin data. Endotoxins (bacterial lipopolysaccharides) are measured by the LAL (Limulus Amebocyte Lysate) assay and reported in EU/mg or EU/mL, under compendial chapter USP <85>, while sterility testing under USP <71> detects viable microorganisms and is a separate test entirely. Their absence from a retatrutide certificate is normal, and must never be read as a guarantee of either.
How do these checks become a transparency score?
Every item above is a documentary property: a field is either printed, batch-specific and verifiable at the source, or it is not. That binary quality is what can be assessed consistently across sellers, and it is all the PeptideTrust scorecard measures. Our methodology sets out the ten weighted criteria used, including named laboratory, batch-level publication, chromatogram availability and independent source verification, so you can see how a certificate like the one described here would be scored. To apply the same checklist in practice, the ranked vendor scoreboard shows which sellers publish documentation of this kind at all.
This guide is educational and concerns laboratory documentation only. The compounds discussed are research chemicals, for research use only. Nothing here is medical advice, and a purity or identity CoA describes the composition of a sample, not its safety.